Rafael Holdings, Inc. (NYSE:RFL) is a company involved in the development and commercialization of novel cancer therapies. It operates in a competitive landscape alongside other biotechnology firms such as Scholar Rock Holding Corporation, Evelo Biosciences, Inc., Verrica Pharmaceuticals Inc., and Replimune Group, Inc. These companies are all striving to innovate in the field of medical treatments, particularly in oncology and related areas.
In evaluating Rafael Holdings' financial efficiency, the Return on Invested Capital (ROIC) is a critical metric. RFL's ROIC is -34.90%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 8.08%. This results in a ROIC to WACC ratio of -4.32, indicating that the company is not generating sufficient returns to cover its cost of capital.
Comparatively, Scholar Rock Holding Corporation (SRRK) has a ROIC of -101.98% and a WACC of 6.91%, leading to a ROIC to WACC ratio of -14.75. This suggests that SRRK is less efficient than RFL in generating returns relative to its cost of capital. Similarly, Evelo Biosciences, Inc. (EVLO) shows a ROIC of -199.73% against a WACC of 9.04%, resulting in a ROIC to WACC ratio of -22.10, the lowest among the peers.
Verrica Pharmaceuticals Inc. (VRCA) stands out with a ROIC of -65.23% and a WACC of 16.08%, yielding a ROIC to WACC ratio of -4.06. Despite being negative, this is the highest ratio among the peer group, indicating relatively better efficiency in managing its capital costs. Replimune Group, Inc. (REPL) also shows inefficiency with a ROIC of -94.11% and a WACC of 7.63%, resulting in a ROIC to WACC ratio of -12.34.
Overall, the analysis reveals that all companies in this peer group, including RFL, are currently generating returns below their cost of capital. However, Verrica Pharmaceuticals Inc. (VRCA) is relatively more efficient compared to the others, as indicated by its less negative ROIC to WACC ratio.
